ArticleERJ open research2025
Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy inJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Current Perspectives onInternational journal of molecular sciences · 2026Review
- Incidence trends of nontuberculous mycobacterial pulmonary infections in Australia, Cambodia, Japan, Thailand, and the United States.medRxiv : the preprint server for health sciences · 2026Article
- Clinical factors and practical strategies to optimize amikacin liposome inhalation suspension therapy in refractory Mycobacterium avium complex pulmonary disease.BMC pulmonary medicine · 2026Article
- Non-Tuberculous Mycobacteria at the Human-Animal-Environment Interface: Antimicrobial Resistance, Environmental Persistence and Cross-Species Exposure Risks.Antibiotics (Basel, Switzerland) · 2026Review
- Comparison of culture and culture-free methods for comprehensive identification of mycobacteria: a single-center prospective study.Journal of clinical microbiology · 2026Article
- Plasmid-mediated macrolide resistance among rapidly growing mycobacteria in Japan.JAC-antimicrobial resistance · 2026Article
- Predictive Value of Nutritional Status in Sputum Culture Conversion Among Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Nontuberculous mycobacterium seroprevalence in Japanese patients with RA.Rheumatology advances in practice · 2026Article
- Association between immunity and antimicrobial treatment resistance in patients with Mycobacterium avium complex pulmonary disease: a multicenter observational study.BMC infectious diseases · 2025Observational
- Developing a Simple Scoring System on CT Findings for Predicting Treatment Failure inOpen forum infectious diseases · 2025Article
- Genotyping and drug susceptibility patterns of Mycobacterium avium subsp. hominissuis isolates from different hosts.Scientific reports · 2025Article
- Serodiagnosis ofIJTLD open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intractable pulmonary diseases with nontuberculous mycobacteria (NTM-PDs) and antimicrobial resistance have become increasingly concerning worldwide. Nevertheless, a surveillance system for NTM has not been established in most countries, thus requiring repeated, intermittent and time-consuming cross-sectional nationwide surveys. Methods: To establish a nationwide surveillance system for NTM-associated diseases, we aimed to develop a prototype computer system primarily designed to continuously estimate NTM-PD incidence using a bacteriological case-defining algorithm through an automatic process of integrating bacteriological data collected from microbiology laboratories across Japan. To validate the accuracy of our study results, we compared the distribution of pulmonary tuberculosis cases between our laboratory data and the national surveillance data, which is representative of the Japanese population. Results: Our estimates implied a 17.7% increase in NTM-PD incidence from 15.8 (14.9-16.8) in 2013 to 19.2 (18.2-20.4) in 2017, per 100 000 population. Moreover, 93.0% of the identified NTM-PD cases were dominated by the Conclusion: These findings, despite being laboratory-based, are extrapolatable to the general population in Japan and provide evidence that supports our system as a viable alternative to the nationwide NTM surveillance system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.